Compare Archer Aviation Inc (ACHR) vs Moderna, Inc. (MRNA) Price & Performance

Archer Aviation (ACHR) trades at $5.37, up 7.83% with a bearish technical signal despite recent momentum. The company shows severe financial strain with -$618.2M net income on minimal $300K revenue in 2025, though analyst sentiment remains optimistic with 78% buy ratings. Recent news highlights progress toward FAA certification for its Midnight eVTOL aircraft, with commercialization targeted for 2028 and a $6B order book providing long-term potential.

The stock presents high-risk speculative potential with significant execution hurdles. While regulatory progress and major partnerships with United Airlines and Stellantis support the bullish case, persistent cash burn and negative margins require substantial capital raises. Investors face binary outcomes dependent on successful certification and commercial deployment timelines against intense competition in the emerging eVTOL market.

Moderna (MRNA) trades at $79.77, up 0.01% on the day, with a bullish technical signal from moving averages and positive momentum from recent pipeline news. The stock has seen significant gains, driven by FDA progress on its mRNA flu vaccine and expansion into oncology and rare diseases. However, fundamentals show persistent losses, with a net income margin of -144.92% in 2025 and declining revenue from pandemic peaks, though quarterly EPS has beaten expectations recently.

The outlook is mixed: strong technical momentum and pipeline diversification offer upside, but high valuation ratios and sustained unprofitability pose risks. Analyst consensus is cautious with a $48.83 price target, suggesting 39% downside, indicating Wall Street sees limited near-term fundamental support despite recent bullish sentiment.